محتوای اصلی مقاله
چکیده
اینترفیرونها خانوادهای از سیتوکینهای اندوکراین و پاراکراین استند که توسط حجرات میزبان در پاسخ به عوامل بیماریزا به ویژه ویروسها و باکتریا ترشح میگردند. اینترفیرونها در حقیقت خط اول دفاعی عضویت را در برابر عفونتهای ویروسی تشکیل میدهند. انترفیرونها مجموعهی از پروتینهای کوچکی هستند که نظر به ساختار جنیتیکی، نحوهی فعالیت، ساختمان و موجودیت آخذههای شان در سطح حجره به سه تایپ I، II و III تقسیمبندی شده اند. در زمان عفونتهای ویروسی مقدار انترفیرونها در عضویت به شدت افزایش مییابد که این عمل نشاندهندهی نقش مهم آنها در کنترول عفونتهای ویروسی میباشد. افزون برفعالیت ضدویروسی، اینترفیرونها بر فعالیت سیستم معافیتی تأثیر گذاشته و رشد تومورها را نیز مهار میکنند. در این مقاله نویسنده تلاش نموده تا ابعاد مختلف فعالیت انترفیرونها را در سیستم معافیتی همراه با خواص، ساختار، انواع و چگونگی عملکرد آنها در جریان عفونتهای ویروسی مورد بحث و بررسی قرار دهد.
کلمات کلیدی
جزئیات مقاله
حق نشر 2024 حق طبع و چاپ برای پوهنتون کابل محفوظ است.

این پروژه تحت مجوز بین المللی Creative Commons Attribution-NonCommercial 4.0 می باشد.
منابع
- M. R. Capobianchi, E. Uleri, C. Caglioti, and A. Dolei, “Type I IFN family members: Similarity, differences and interaction,” Cytokine Growth Factor Rev., 2015, doi: 10.1016/j.cytogfr.2014.
- U. Schleicher et al., “Type I interferon signaling is required for CpG-oligodesoxynucleotide-induced control of Leishmania major, but not for spontaneous cure of subcutaneous primary or secondary L. major infection,” Front. Immunol., 2018.
- A. Garcia-Diaz et al., “Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression,” Cell Rep., 2017.
- A. Isaacs and J. Lindenmann, “Virus interference. I. The interferon,” J. Interferon Res., 1987.
- T. Kawai and S. Akira, “Toll-like receptor and RIG-1-like receptor signaling,” Annals of the New York Academy of Sciences. 2008.
- E. C. Borden et al., “Interferons at age 50: Past, current and future impact on biomedicine,” Nature Reviews Drug Discovery. 2007.
- E. F. Wheelock, “Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin,” Science (80-. )., 1965.
- M. M. Freshman, T. C. Merigan, J. S. Remington, and I. E. Brownlee, “In vitro and in vivo Antiviral Action of an Interferon-Like Substance Induced by Toxoplasma gondii,” Proc. Soc. Exp. Biol. Med., 1966.
- L. Prokunina-Olsson et al., “A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus,” Nat. Genet., 2013.
- J. C. Hall and A. Rosen, “Type i interferons: Crucial participants in disease amplification in autoimmunity,” Nature Reviews Rheumatology. 2010.
- R. Broering et al., “The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response,” Gut, 2010.
- W. Hou et al., “Lambda Interferon Inhibits Human Immunodeficiency Virus Type 1 Infection of Macrophages,” J. Virol., 2009.
- P. Marrack, J. Kappler, and T. Mitchell, “Type I interferons keep activated T cells alive,” J. Exp. Med., 1999.
- A. A. Lin, P. K. Tripathi, A. Sholl, M. B. Jordan, and D. A. Hildeman, “Gamma Interferon Signaling in Macrophage Lineage Cells Regulates Central Nervous System Inflammation and Chemokine Production,” J. Virol., 2009.
- H. Nakajima et al., “Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration,” Vaccine, 2012.
- E. Tomasello, E. Pollet, T. P. Vu Manh, G. Uzé, and M. Dalod, “Harnessing mechanistic knowledge on beneficial versus deleterious IFN-I effects to design innovative immunotherapies targeting cytokine activity to specific cell types,” Front. Immunol., 2014.
- L. M. Snell, T. L. McGaha, and D. G. Brooks, “Type I Interferon in Chronic Virus Infection and Cancer,” Trends in Immunology. 2017.
منابع
M. R. Capobianchi, E. Uleri, C. Caglioti, and A. Dolei, “Type I IFN family members: Similarity, differences and interaction,” Cytokine Growth Factor Rev., 2015, doi: 10.1016/j.cytogfr.2014.
U. Schleicher et al., “Type I interferon signaling is required for CpG-oligodesoxynucleotide-induced control of Leishmania major, but not for spontaneous cure of subcutaneous primary or secondary L. major infection,” Front. Immunol., 2018.
A. Garcia-Diaz et al., “Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression,” Cell Rep., 2017.
A. Isaacs and J. Lindenmann, “Virus interference. I. The interferon,” J. Interferon Res., 1987.
T. Kawai and S. Akira, “Toll-like receptor and RIG-1-like receptor signaling,” Annals of the New York Academy of Sciences. 2008.
E. C. Borden et al., “Interferons at age 50: Past, current and future impact on biomedicine,” Nature Reviews Drug Discovery. 2007.
E. F. Wheelock, “Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin,” Science (80-. )., 1965.
M. M. Freshman, T. C. Merigan, J. S. Remington, and I. E. Brownlee, “In vitro and in vivo Antiviral Action of an Interferon-Like Substance Induced by Toxoplasma gondii,” Proc. Soc. Exp. Biol. Med., 1966.
L. Prokunina-Olsson et al., “A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus,” Nat. Genet., 2013.
J. C. Hall and A. Rosen, “Type i interferons: Crucial participants in disease amplification in autoimmunity,” Nature Reviews Rheumatology. 2010.
R. Broering et al., “The interferon stimulated gene 15 functions as a proviral factor for the hepatitis C virus and as a regulator of the IFN response,” Gut, 2010.
W. Hou et al., “Lambda Interferon Inhibits Human Immunodeficiency Virus Type 1 Infection of Macrophages,” J. Virol., 2009.
P. Marrack, J. Kappler, and T. Mitchell, “Type I interferons keep activated T cells alive,” J. Exp. Med., 1999.
A. A. Lin, P. K. Tripathi, A. Sholl, M. B. Jordan, and D. A. Hildeman, “Gamma Interferon Signaling in Macrophage Lineage Cells Regulates Central Nervous System Inflammation and Chemokine Production,” J. Virol., 2009.
H. Nakajima et al., “Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration,” Vaccine, 2012.
E. Tomasello, E. Pollet, T. P. Vu Manh, G. Uzé, and M. Dalod, “Harnessing mechanistic knowledge on beneficial versus deleterious IFN-I effects to design innovative immunotherapies targeting cytokine activity to specific cell types,” Front. Immunol., 2014.
L. M. Snell, T. L. McGaha, and D. G. Brooks, “Type I Interferon in Chronic Virus Infection and Cancer,” Trends in Immunology. 2017.